Clinical trial
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month…
NCT00268892 · Ferring Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00268892 |
|---|---|
| Title | Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer |
| Official title | An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens in Patients With Prostate Cancer |
| Lead sponsor | Ferring Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Degarelix |
| Enrollment | 278 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Dec 23, 2005 |
| Last update posted | Dec 24, 2010 |
| Countries | Belgium, Finland, France, Germany, Montenegro, Netherlands, Romania, Russia, Serbia, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: